MXPA04001777A - Nuevas sales de bisulfato de piperidin-2, 6-diona y suuso para tratamiento de trastornos efectivos relacionados con estres. - Google Patents

Nuevas sales de bisulfato de piperidin-2, 6-diona y suuso para tratamiento de trastornos efectivos relacionados con estres.

Info

Publication number
MXPA04001777A
MXPA04001777A MXPA04001777A MXPA04001777A MXPA04001777A MX PA04001777 A MXPA04001777 A MX PA04001777A MX PA04001777 A MXPA04001777 A MX PA04001777A MX PA04001777 A MXPA04001777 A MX PA04001777A MX PA04001777 A MXPA04001777 A MX PA04001777A
Authority
MX
Mexico
Prior art keywords
bisulfate
dione
dimethylpiperidin
sleep
bisulfate salt
Prior art date
Application number
MXPA04001777A
Other languages
English (en)
Spanish (es)
Inventor
Ward Gittos Maurice
Original Assignee
Prestwick Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prestwick Pharmaceuticals Inc filed Critical Prestwick Pharmaceuticals Inc
Publication of MXPA04001777A publication Critical patent/MXPA04001777A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86—Oxygen atoms
    • C07D211/88—Oxygen atoms attached in positions 2 and 6, e.g. glutarimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
MXPA04001777A 2001-08-28 2002-08-22 Nuevas sales de bisulfato de piperidin-2, 6-diona y suuso para tratamiento de trastornos efectivos relacionados con estres. MXPA04001777A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0120821A GB2379216A (en) 2001-08-28 2001-08-28 Piperidin-2,6-dione salts useful for the treatment of stress-related affective disorders
PCT/GB2002/003869 WO2003020275A1 (en) 2001-08-28 2002-08-22 Novel piperidin-2,6-dione bisulphate salts and their use for the treatment of stress-related affective disorders

Publications (1)

Publication Number Publication Date
MXPA04001777A true MXPA04001777A (es) 2004-11-22

Family

ID=9921084

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04001777A MXPA04001777A (es) 2001-08-28 2002-08-22 Nuevas sales de bisulfato de piperidin-2, 6-diona y suuso para tratamiento de trastornos efectivos relacionados con estres.

Country Status (19)

Country Link
US (1) US7189742B2 (el)
EP (1) EP1420788B1 (el)
JP (1) JP2005502677A (el)
KR (1) KR100906893B1 (el)
CN (1) CN100506229C (el)
AT (1) ATE347891T1 (el)
AU (1) AU2002321522B2 (el)
BR (1) BR0212175A (el)
CA (1) CA2459009C (el)
CY (1) CY1105979T1 (el)
DE (1) DE60216776T2 (el)
DK (1) DK1420788T3 (el)
ES (1) ES2275898T3 (el)
GB (1) GB2379216A (el)
IL (2) IL160615A0 (el)
MX (1) MXPA04001777A (el)
NZ (1) NZ531345A (el)
PT (1) PT1420788E (el)
WO (1) WO2003020275A1 (el)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0219639D0 (en) * 2002-08-22 2002-10-02 Prestwick Scient Capital Inc Novel piperidin-2,6-dione salts and their use for the treatment of stress-related affective disorders
US7560861B2 (en) 2004-05-03 2009-07-14 Lg Electronics Inc. Organic electro-luminescence display device with an organic electro-luminescence array and fabricating method thereof
KR100938296B1 (ko) * 2005-03-15 2010-01-22 에프. 호프만-라 로슈 아게 5ｈｔ5ａ 수용체 길항제로서의2-아닐리노-3,4-다이하이드로-퀴나졸린의 용도
GB0518763D0 (en) * 2005-09-14 2005-10-19 Prestwick Pharmaceuticals Inc Treatment of hypertension
KR101401612B1 (ko) * 2012-04-30 2014-06-02 재단법인 전남생물산업진흥원 석류 추출물을 유효성분으로 포함하는 스트레스성 질환의 치료 및 예방용 조성물
US20160051639A1 (en) * 2014-08-25 2016-02-25 Aimmune Therapeutics, Inc. Egg protein formulations and methods of manufacture thereof
WO2017087691A1 (en) 2015-11-17 2017-05-26 The Trustees Of Columbia University In The City Of New York Pharmacological prophylactics against stress-induced affective disorders and their associated symptoms
WO2019094596A1 (en) 2017-11-09 2019-05-16 The Trustees Of Columbia University In The City Of New York Biomarkers for efficacy of prophylactic treatments against stress-induced affective disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3693729A (en) * 1970-02-19 1972-09-26 Global Marine Inc Air cushion drilling vehicle
GB1455687A (en) * 1972-12-28 1976-11-17 Aspro Nicholas Ltd Pharmacologically active 3-phenyl-3-aminoalkyl-2,6-dioxo-hydro genated pyridines
EP0216555B1 (en) * 1985-09-11 1992-09-02 Btg International Limited Use of dioxopiperidine derivatives in the treatment of anxiety, for the reduction of chronic abnormally high brain levels of serotonin or 5-hydroxy-indoleacetic acid, and in the treatment of bacterial or viral infections
EP0263594B1 (en) * 1986-09-08 1992-06-24 Btg International Limited Anxiolytic compositions containing dioxopiperidine derivatives
US5104990A (en) * 1990-02-27 1992-04-14 G. D. Searle & Co. Process for the preparation of 3-aryl-3-aminoalkyl-2,6-dioxohexahydropyridines

Also Published As

Publication number Publication date
DE60216776T2 (de) 2007-10-04
CA2459009C (en) 2010-04-06
IL160615A0 (en) 2004-07-25
IL160615A (en) 2008-08-07
KR100906893B1 (ko) 2009-07-08
JP2005502677A (ja) 2005-01-27
DE60216776D1 (de) 2007-01-25
DK1420788T3 (da) 2007-02-26
GB0120821D0 (en) 2001-10-17
US7189742B2 (en) 2007-03-13
US20040249159A1 (en) 2004-12-09
GB2379216A (en) 2003-03-05
ATE347891T1 (de) 2007-01-15
CN1549715A (zh) 2004-11-24
EP1420788A1 (en) 2004-05-26
ES2275898T3 (es) 2007-06-16
CN100506229C (zh) 2009-07-01
WO2003020275A1 (en) 2003-03-13
BR0212175A (pt) 2004-07-20
NZ531345A (en) 2005-07-29
CA2459009A1 (en) 2003-03-13
PT1420788E (pt) 2007-03-30
EP1420788B1 (en) 2006-12-13
AU2002321522B2 (en) 2006-10-12
CY1105979T1 (el) 2011-04-06
KR20040031000A (ko) 2004-04-09

Similar Documents

Publication Publication Date Title
DE3650733T2 (de) Pharmazeutische Zubereitungen und medizinische Verwendungen von Dioxopiperidinderivaten, insbesondere als Verstärker der Immunantwort sowie als antivirale und antibakterielle Wirkstoffe
US20090182012A1 (en) Piperidin-2, 6-dione pamoate salts and their use for the treatment of affective disorders
MXPA04001777A (es) Nuevas sales de bisulfato de piperidin-2, 6-diona y suuso para tratamiento de trastornos efectivos relacionados con estres.
AU2002321522A1 (en) Novel piperidin-2,6-dione bisulphate salts and their use for the treatment of stress-related affective disorders
WO1997034603A1 (en) USE OF (+)-α-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL IN TREATING DEPRESSIVE DISORDERS AND BIPOLAR DISORDERS
FR2544614A1 (fr) Nouvelle association medicamenteuse pour le traitement de l'hypertension
AU2003255947B2 (en) Piperidin-2,6-dione pamoate salts and their use for the treatment of stress-related affective disorders
EP2393778B1 (en) Optically active 3-[(phenylpiperazin-1-yl)alkyl]-3- alkyl-oxindole derivatives having CNS activity
EA012443B1 (ru) Фармацевтическая композиция, включающая 1-(3-хлорфенил)-3-алкилпиперазин, для лечения расстройств аппетита
WO2007031737A1 (en) 4,4-dimethylpiperidine-2,6-dione derivatives for use in the treatment of hypertension
EA022828B1 (ru) Способ получения соли лоркасерина и фталевой кислоты, продукт способа, фармацевтические композиции для лечения и/или профилактики нарушений, связанных с ожирением, их применение и способы лечения и/или профилактики нарушений, связанных с ожирением

Legal Events

Date Code Title Description
FG Grant or registration